The patent is groundbreaking because ANVS402 offers significant advantages over the previous, less structured form, including better stability, higher purity, and longer half-life, improving buntanetap’s effectiveness. ANVS402 is covered by a composition of matter claim as well as multiple claims for chronic and acute neurodegenerative diseases and for neuropsychiatric indications.

The composition of matter patent is the single most important patent for any pharmaceutical company developing a new drug. Approval of this patent will come with protection of ANVS402 and all its uses for a 20-year patent term.

“A new 20-year patent term means that we will be able to continue working on our robust pipeline, developing novel drug therapies for many of neurodegenerative diseases,” said Maria Maccecchini, Ph.D., CEO of Annovis.

The mechanism of action, favorable toxicology profile and mode of administration of Annovis’ drug, position it as a leader among the current drugs on the market and in development. While those drugs have shown little efficacy in reversing neurodegenerative diseases, only slowing progression by attempting to remove just one neurotoxic protein, buntanetap has been shown to effectively stop the synthesis of four neurotoxic proteins: Amyloid Beta, Tau, alpha Synuclein, and TDP43, the culprits behind nerve cell degeneration and death. Buntanetap early trials have shown its ability to reverse destructive effects these diseases have on thinking, memory, movement, and more.

Annovis enters an ecosystem where the only two disease-modified drugs that exist have shown well-documented, serious side effects, like amyloid-related imaging abnormalities (ARIA), which can manifest as brain swelling or bleeding. In contrast, buntanetap has been well-tolerated with low side effects (no drug-related SAEs, or serious adverse events) and each AE (adverse event) less than 2 percent in clinical trials. Buntanetap is more easily administered than its competitors’ (a single pill a day versus intravenous infusions) and, as a result, Annovis has observed rapid trial enrollment, with a low dropout rate of 6 percent, and high rates of patient compliance.

Currently, Annovis is conducting ongoing clinical trials of its lead drug candidate buntanetap: a phase III study is testing the medication in early Parkinson’s Disease, and a phase II/III study is testing the medication in moderate Alzheimer’s Disease. ANVS402 is expected to replace buntanetap in future PD and AD clinical trials after completion of a bridging study in early 2024. In addition, the phase III Parkinson’s Disease study recently received a positive safety review from the Data and Safety Monitoring Board (DSMB).

“Annovis is extremely excited about the potential of ANVS402 and its future iterations in the treatment of neurodegenerative diseases,” said Michael Hoffman, chairman of Annovis.

About Annovis Bio, Inc.
Headquartered in Berwyn, Pa., Annovis Bio, Inc.is a clinical-stage, drug platform company addressing neurodegeneration, such as Alzheimer’s Disease (AD), Parkinson’s Disease (PD), and other chronic neurodegenerative diseases. It is believed to be the only company developing a drug for both AD and PD designed to inhibit more than one neurotoxic protein to restore axonal and synaptic activity. By improving brain function, the company’s goal is to treat memory loss and dementia associated with AD as well as body and brain dysfunction associated with PD. For information about the company’s clinical trials and patents, visit anovisbio.com, and follow the company on LinkedIn and Twitter.

Click here to learn more.

Contacts

Investor Contact:
Laura Feragen
Jacobson Strategic Health
laura@jacobsonstrategic.com
267-262-4309